SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.87-2.3%Dec 5 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9308)10/22/2003 1:22:20 PM
From: tuck  Read Replies (1) of 52153
 
Peter,

MT100 is POZN's other lead candidate, currently under review in Britain, where the MCA has sent something called a "letter of comments." Does anyone here know the implications of this? MT100's market is almost 10x bigger than MT300, the one the FDA slammed. I would think that the announcement of the receipt of this letter, mentioned in the same PR as the FDA action, may have had a lot to do with POZN's haircut.

I would have bought, too, but for my uncertainty about that. Thoughts?

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News